See more : China Glaze Co.,Ltd. (1809.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Neighbourly Pharmacy Inc. (NBLY.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neighbourly Pharmacy Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Longfor Group Holdings Limited (LGFRY) Income Statement Analysis – Financial Results
- Niko Semiconductor Co., Ltd. (3317.TWO) Income Statement Analysis – Financial Results
- Landmark Infrastructure Partners LP (LMRKP) Income Statement Analysis – Financial Results
- Shanghai Tongda Venture Capital Co., Ltd. (600647.SS) Income Statement Analysis – Financial Results
- First Choice Bancorp (FCBP) Income Statement Analysis – Financial Results
Neighbourly Pharmacy Inc. (NBLY.TO)
About Neighbourly Pharmacy Inc.
Neighbourly Pharmacy Inc. owns and operates a chain of retail pharmacies in Canada. The company sells prescription medication, confections and food, over the counter drugs, and health and beauty aids. It operates pharmacies in 275 locations under the various banners, such as IDA/Guardian, Pharmachoice, Pharmasave, Remedy's RX, and Drug Trading. The company was incorporated in 2015 and is headquartered in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 749.15M | 427.51M | 306.49M | 186.63M | 150.13M | 92.64M |
| Cost of Revenue | 456.42M | 269.04M | 191.78M | 114.33M | 87.32M | 52.99M |
| Gross Profit | 292.73M | 158.47M | 114.72M | 72.29M | 62.81M | 39.65M |
| Gross Profit Ratio | 39.07% | 37.07% | 37.43% | 38.74% | 41.84% | 42.80% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 218.39M | 117.36M | 79.82M | 51.27M | 48.39M | 27.55M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 218.39M | 117.36M | 79.82M | 51.27M | 48.39M | 27.55M |
| Other Expenses | 448.00K | -67.23M | -80.41M | -13.58M | -9.22M | -5.34M |
| Operating Expenses | 278.22M | 142.72M | 98.94M | 65.05M | 61.17M | 34.60M |
| Cost & Expenses | 734.64M | 411.76M | 290.72M | 179.39M | 148.48M | 87.59M |
| Interest Income | 37.00K | 29.00K | 31.00K | 64.00K | 14.00K | 6.00K |
| Interest Expense | 23.45M | 10.39M | 16.04M | 12.52M | 10.77M | 7.20M |
| Depreciation & Amortization | 59.84M | 25.35M | 19.12M | 13.78M | 12.77M | 7.05M |
| EBITDA | 81.25M | -26.09M | -45.48M | 7.51M | 5.21M | 6.77M |
| EBITDA Ratio | 10.85% | -6.10% | -14.84% | 4.02% | 3.47% | 7.31% |
| Operating Income | -5.10M | -11.21M | 8.48M | 3.12M | -4.07M | -8.52M |
| Operating Income Ratio | -0.68% | -2.62% | 2.77% | 1.67% | -2.71% | -9.20% |
| Total Other Income/Expenses | -33.87M | -94.19M | -96.41M | -26.04M | -25.69M | -12.53M |
| Income Before Tax | -19.36M | -78.44M | -87.93M | -22.92M | -24.04M | -21.05M |
| Income Before Tax Ratio | -2.58% | -18.35% | -28.69% | -12.28% | -16.01% | -22.72% |
| Income Tax Expense | -4.56M | -6.04M | 2.59M | 422.00K | -1.28M | -3.01M |
| Net Income | -15.50M | -73.36M | -91.33M | -23.34M | -22.76M | -18.04M |
| Net Income Ratio | -2.07% | -17.16% | -29.80% | -12.51% | -15.16% | -19.47% |
| EPS | -0.37 | -2.57 | -2.73 | -0.70 | -0.68 | -0.54 |
| EPS Diluted | -0.37 | -2.57 | -2.73 | -0.70 | -0.68 | -0.54 |
| Weighted Avg Shares Out | 41.81M | 28.51M | 33.44M | 33.44M | 33.44M | 33.44M |
| Weighted Avg Shares Out (Dil) | 41.81M | 28.51M | 33.44M | 33.44M | 33.44M | 33.44M |
Source: https://incomestatements.info
Category: Stock Reports